Former FDA Commissioner Scott Gottlieb, MD, emphasized testing, contact tracing, and treatment to address coronavirus disease 2019 (COVID-19); US pediatric practices have struggled during the pandemic; FDA approves first saliva-based coronavirus test.
In advising lawmakers, governors, and members of the Trump administration on how to return to normalcy amid the economic lockdown caused by the coronavirus disease 2019 (COVID-19), former FDA Commissioner Scott Gottlieb emphasized the importance of 3 T’s: testing, contact tracing, and treatment. Reported in The Washington Post, Gottlieb noted that if business leaders are seeking to reopen state economies, companies should reduce potential risks to their employees and society by providing rapid COVID-19 tests at work and guaranteeing sick leave for those infected.
Reported in Kaiser Health News, thousands of pediatric practices that provide front-line care for US children have been struggling to adapt to the COVID-19 pandemic, which has caused significant loss of revenue and shortages of protective equipment. Berkeley Pediatrics, a 78-year-old practice in Berkeley, California, noted that patient volume has dropped nearly 60% since San Francisco Bay Area officials issued the first shelter-in-place order. With the office scrambling to set up telehealth services for sick visits, 6 physicians have already been laid off, and all have taken a 40% pay cut.The first saliva-based coronavirus test, from the Rutgers University lab RUCDR Infinite Biologics, was issued emergency-use authorization by the FDA Monday and will be available through hospitals and clinics associated with the university, according to The Associated Press. As opposed to current testing which requires samples from a patient’s nose or throat, patients will spit in a tube several times to provide the sample. Andrew Brooks, who directs the Rutgers lab, highlighted that the test “prevents health care professionals from having to actually be in the face of somebody that is symptomatic.”
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More
2 Commerce Drive
Cranbury, NJ 08512